A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors

Seven different anti–PD-1 and PD-L1 mAbs are now widely used in the United States to treat a variety of cancer types, but no clinical trials have compared them directly. Furthermore, because many of these Abs do not cross-react between mouse and human proteins, no preclinical models exist in which t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barham, Whitney, Hsu, Michelle, Liu, Xin, Harrington, Susan M., Hirdler, Jacob B., Gicobi, Joanina K., Zhu, Xingxing, Zeng, Hu, Pavelko, Kevin D., Yan, Yiyi, Mansfield, Aaron S., Dong, Haidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AAI 2023
Materias:
Clinical and Translational Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106088/
https://www.ncbi.nlm.nih.gov/pubmed/36656137
http://dx.doi.org/10.4049/immunohorizons.2200054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106088/
https://www.ncbi.nlm.nih.gov/pubmed/36656137
http://dx.doi.org/10.4049/immunohorizons.2200054

Ejemplares similares